News
No ‘one-size-fits-all’ approach to mental health, says expert
We’ve still got a long way to go, says Mind associate director of external relations Vicki Nash
There is no one-size-fits-all approach to mental health, the associate director of external relations at charity Mind has said, as a growing number of women are turning to digital support tools.
In an interview with Femtech World during the Women’s Health Innovation Summit UK, Vicki Nash said more and more mental health and wellbeing apps are popping up, as more awareness are prompting people to seek help.
“We’ve seen interesting developments in AI and virtual reality and how those might be able to help with particular conditions or in particular situations,” Nash said.
“But while online solutions work for some, they definitely don’t work for others.
“Quite often what we’re finding is particularly because of the benefits and cost savings, more people are being directed to online services.
“However, I think we need to keep our finger on the pulse and look at what the opportunities are while making sure people get the support they need. There’s no one-size-fits-all approach.”
While data shows the pandemic has marked a rise in the use of digital mental health tools and technologies, Nash said it is important that people have choice and availability.
“Women have told us that actually they want to have blended offers so they can pick and choose and combine their support services as best as possible.
“They do want some online support, but they also want that face-to-face contact. It’s about being able to dip in and out of services.”
The associate director recognised the “real progress” around people understanding mental health, but she said there is still a lot of work to do.
“Women are definitely feeling that they are able to talk more openly about their mental health, but we know that that’s not the case for everyone,” she said.
“We have a better understanding of mental health problems like anxiety and depression, but we are certainly not talking enough about more stigmatised conditions like schizophrenia or psychosis.
“We’ve still got a long way to go to make sure that everyone gets the support and respect they deserve.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Fertility2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







Pingback: Poor mental health linked to increased risk of preterm birth- study - FemTech World